Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $152.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 163.67% to $152.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $405.3 million, a 90.35% increase, with the full-year FY2025 number at $405.3 million, up 90.35% from a year prior.
  • Change in Acquisitions & Divestments was $152.9 million for Q4 2025 at Janux Therapeutics, up from $126.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $152.9 million in Q4 2025 to a low of $22.1 million in Q3 2021.
  • A 5-year average of $77.2 million and a median of $76.0 million in 2022 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 427.21% in 2022, then plummeted 52.89% in 2024.
  • Janux Therapeutics' Change in Acquisitions & Divestments stood at $112.0 million in 2021, then dropped by 22.77% to $86.5 million in 2022, then crashed by 48.27% to $44.8 million in 2023, then grew by 29.61% to $58.0 million in 2024, then skyrocketed by 163.67% to $152.9 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Change in Acquisitions & Divestments are $152.9 million (Q4 2025), $126.4 million (Q3 2025), and $94.7 million (Q2 2025).